

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	10553627
<b>Application Number:</b>	10565713
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	7929
<b>Title of Invention:</b>	Substituted 2-aminotetralin for the treatment of depression
<b>First Named Inventor/Applicant Name:</b>	Dieter Scheller
<b>Customer Number:</b>	28997
<b>Filer:</b>	Molly Banahan Edwards/Lisa Buchhold
<b>Filer Authorized By:</b>	Molly Banahan Edwards
<b>Attorney Docket Number:</b>	6102-000008/US/NP
<b>Receipt Date:</b>	19-JUL-2011
<b>Filing Date:</b>	25-JAN-2006
<b>Time Stamp:</b>	17:15:27
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	4171
Deposit Account	080750
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Amendment/Req. Reconsideration-After Non-Final Reject	Response_to_Office_Action_dated_19_April_2011.PDF	135970 f8729569a683c40c0f07018e3e179183cc4d2977	no	16
Warnings:					
Information:					
2	Non Patent Literature	Belluzzi1984_Abtract.PDF	36807 c785ef80fc495929a9ac7195132aa17e9d92cc0	no	1
Warnings:					
Information:					
3	Non Patent Literature	Beaulieu1984_Abtract.PDF	79045 a6df21ef7ccf05675a8e383b9bee8d57d775ef61	no	1
Warnings:					
Information:					
4	Non Patent Literature	BertainaAnglade2006.PDF	323012 8d67317f7a8c47f0c0407b18050deb066d0eae31	no	9
Warnings:					
Information:					
5	Non Patent Literature	Corrigan2000.PDF	780687 a64c2461e629db2d17ef43d06e84ca140342397e	no	8
Warnings:					
Information:					
6	Non Patent Literature	Goetz2003.PDF	1070342 c69b9e425781f815074800a3495821e40c326f0b	no	13
Warnings:					
Information:					
7	Non Patent Literature	Muscat1992_Abtract.PDF	80998 4d1c29ac933cb2c484c4c2f2d4ff73d92eea2ae7	no	1
Warnings:					
Information:					
8	Non Patent Literature	Mayoclinic_Rotigotine2007.PDF	307336 a560b4fd9bce0501c4df022c80b43be3887e984	no	8

Warnings:					
Information:					
9	Non Patent Literature	Scheller2009.PDF	402765	no	14
			cfa4319661e667b107f84098ed6c445689b dbbca		
Warnings:					
Information:					
10	Non Patent Literature	Wang2007.PDF	525862	no	8
			d6290df7598c5f0e7cc085c536fb6b4828aa d8b7		
Warnings:					
Information:					
11	Non Patent Literature	Wikipedia_Apomorphine_print ed_May_05_2011.PDF	99270	no	6
			884f5744200e8bd07e1f60fc78783f67a66ff 02f		
Warnings:					
Information:					
12	Non Patent Literature	000078USOA1112002.PDF	359418	no	10
			a30225b56c851f8037e70d6fff9ff8e9785a8 ad0		
Warnings:					
Information:					
13	Non Patent Literature	000078USDVAOA9132007.PDF	536349	no	14
			fe6dda61af3adee98718b76a37833fd8a7f7 1acf		
Warnings:					
Information:					
14	Non Patent Literature	000078USDVAOA512008.PDF	758366	no	21
			2d1bd4b3236d8f74ac2e02eb2e6cefe23ea 667f5		
Warnings:					
Information:					
15	Non Patent Literature	000034USNPOA10162008.PDF	6846058	no	132
			27ab62dc9f3e184f531c0b0c552f09bb4df8 94dc		
Warnings:					
Information:					
16	Non Patent Literature	000078USDVAOA1262009.PDF	4028454	no	93
			1eae8804f297d10519609d02ba60de3e15e b6f17		
Warnings:					
Information:					
17	Non Patent Literature	000034USNPOA922009.PDF	396622	no	11
			3025b078919546c35dd589c00bed9def9d9 5f507		

Warnings:					
Information:					
18	Non Patent Literature	000009USNPOA10232009.PDF	386450	no	12
			305ec99d2e336407191894bcad0e1d6f9defa283		
Warnings:					
Information:					
19	Non Patent Literature	000078USDVAOA1162009.PDF	1190805	no	32
			0d9f60f201e3105f3512a57fcdcb2beb680bb692f		
Warnings:					
Information:					
20	Non Patent Literature	000009USNPOA05272010.PDF	506423	no	15
			b2fc0d125e614a638c54c912c0b381fd4e4a9778		
Warnings:					
Information:					
21	Non Patent Literature	000034USNPOA6072010.PDF	660243	no	15
			5de764f095e9a97eb65a44005908a5d2be92bbdb		
Warnings:					
Information:					
22	Non Patent Literature	000078USDVAOA1082010.PDF	989048	no	25
			f8156888e3290c8356b06034d37f72923a6b9574		
Warnings:					
Information:					
23	Non Patent Literature	000009USNPOA02142011.PDF	630491	no	18
			f09c4cb9ffc81bb3500d8af4530ea8c699d9fb259		
Warnings:					
Information:					
24		SupplementalIDS_with_Form1449.PDF	55212	yes	4
			e1fc5f3715d6c9450f0c8185014d6be0d4fb363		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Transmittal Letter		1	2	
	Information Disclosure Statement (IDS) Form (SB08)		3	4	
Warnings:					
Information:					

25	Fee Worksheet (SB06)	fee-info.pdf	30024 80e8f6c367a58a7f9a781fef11a5a136e52a70	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			21216057		
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  <b>If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</b></p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  <b>If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</b></p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>  <b>If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</b></p>					